Welcome to our dedicated page for NEUROCRINE BIOSCIENCES SEC filings (Ticker: NBIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Neurocrine Biosciences Inc. filings document the regulatory record of a commercial biopharmaceutical company developing and selling treatments for neurological, psychiatric, endocrine and immunological disorders. Its 8-K reports cover operating and financial results, product-sales disclosures, clinical or regulatory updates, material agreements, capital-structure matters and executive or employment-related governance events.
Proxy filings describe board matters, shareholder voting items, executive compensation, equity awards and pay-versus-performance disclosures. The filing record also includes formal disclosures related to INGREZZA, CRENESSITY and the company's pipeline, as well as risk, governance and transaction-related disclosure categories relevant to its public-company status.
POON CHRISTINE A reported acquisition or exercise transactions in this Form 4 filing.
NEUROCRINE BIOSCIENCES INC director Christine A. Poon reported an equity compensation grant of 2,567 Restricted Stock Units. Each RSU represents one share of common stock upon vesting, and the entire award is scheduled to vest in full on May 27, 2027.
Sharp Shalini reported acquisition or exercise transactions in this Form 4 filing.
Neurocrine Biosciences director Shalini Sharp received a grant of 2,567 restricted stock units (RSUs). Each RSU represents one share of common stock upon vesting, and the entire award will vest on May 27, 2027. This is a stock-based compensation grant, not an open-market share purchase or sale, and leaves her with 2,567 RSUs reported as directly held.
SHERWIN STEPHEN A reported acquisition or exercise transactions in this Form 4 filing.
NEUROCRINE BIOSCIENCES INC director Stephen A. Sherwin received a grant of 2,567 restricted stock units. These RSUs give him the right to receive an equal number of Neurocrine common shares when they vest. According to the award terms, the RSUs will vest in full on May 27, 2027, and he will then receive 2,567 shares if he remains eligible under the plan.
MORROW GEORGE J reported acquisition or exercise transactions in this Form 4 filing.
NEUROCRINE BIOSCIENCES INC director George J. Morrow received a grant of 2,567 Restricted Stock Units as equity compensation. Each RSU represents the right to receive one share of the company’s common stock upon vesting. The RSUs will vest in full on May 27, 2027, and the filing shows 2,567 derivative shares held directly after this award.
RASTETTER WILLIAM H reported acquisition or exercise transactions in this Form 4 filing.
Neurocrine Biosciences director William H. Rastetter received a grant of 2,567 Restricted Stock Units (RSUs). Each RSU represents one share of Neurocrine’s common stock when it vests. The award was made at no cash cost per unit and is held as a direct derivative position.
The RSUs will vest in full on May 27, 2027, meaning Rastetter will receive 2,567 common shares on that date if vesting conditions are satisfied. Following this grant, his reported derivative holdings from this award total 2,567 RSUs.
NEUROCRINE BIOSCIENCES INC director Leslie V. Norwalk received new equity awards. On May 27, 2026, Norwalk was granted 2,624 non-qualified stock options for common stock with an exercise price of $155.83 per share, expiring on May 27, 2036. These options vest in 12 monthly installments beginning on June 27, 2026.
Norwalk was also granted 1,284 Restricted Stock Units (RSUs), each representing the right to receive one share of common stock upon vesting. The RSUs will vest in full on May 27, 2027. These awards are compensation-related grants rather than open-market purchases or sales.
NEUROCRINE BIOSCIENCES INC Chief Corp. Affairs Officer David W. Boyer reported an open-market sale of 3,888 shares of common stock. The shares were sold at a weighted average price of $156.6418 per share in multiple trades between $155.81 and $157.62.
The transaction was executed by a broker under a pre-arranged Rule 10b5-1 trading plan adopted on February 23, 2026, which the company’s policy does not allow him to amend after adoption. Following this sale, Boyer directly holds 7,799 shares, including 106 shares acquired through the company’s 2018 Employee Stock Purchase Plan.
Neurocrine Biosciences, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on May 27, 2026. Stockholders elected three Class III directors for terms expiring at the 2029 Annual Meeting and confirmed the existing Class I and Class II board structure.
Of 100,581,991 shares entitled to vote as of March 31, 2026, 90,118,625 were represented in person or by proxy. Stockholders approved on an advisory basis the compensation of named executive officers, and they approved the Amended 2025 Equity Incentive Plan as described in the company’s definitive proxy statement.
Stockholders also ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, confirming the company’s current external audit relationship.